| Tumor immunogenic cell death as a mediator of intratumor CD8 T-cell recruitment N Roussot, F Ghiringhelli, C Rébé Cells 11 (22), 3672, 2022 | 19 | 2022 |
| Clinical utility of genomic tests evaluating homologous recombination repair deficiency (HRD) for treatment decisions in early and metastatic breast cancer L Galland, N Roussot, I Desmoulins, D Mayeur, C Kaderbhai, S Ilie, ... Cancers 15 (4), 1299, 2023 | 9 | 2023 |
| Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy SM Ilie, N Briot, G Constantin, N Roussot, A Ilie, A Bergeron, L Arnould, ... Breast Cancer 30 (6), 997-1007, 2023 | 3 | 2023 |
| Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer., 2023, 15, 1299 L Galland, N Roussot, I Desmoulins, D Mayeur, C Kaderbhai, S Ilie, ... DOI: https://doi. org/10.3390/cancers15041299, 2011 | 3 | 2011 |
| A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer N Roussot, JD Fumet, E Limagne, M Thibaudin, A Hervieu, A Hennequin, ... BMC cancer 23 (1), 1080, 2023 | 2 | 2023 |
| FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy N Roussot, J Vincent, R Palmier, G Constantin, L Bengrine, JD Fumet, ... Frontiers in Oncology 13, 2023 | 2 | 2023 |
| FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report N Roussot, J Lecuelle, L Dalens, C Truntzer, F Ghiringhelli Journal for Immunotherapy of Cancer 11 (10), 2023 | 1 | 2023 |
| Effect of radiochemotherapy on peripheral immune response in glioblastoma L Hampe, S Daumoine, E Limagne, N Roussot, F Borsotti, J Vincent, S Ilie, ... Cancer Immunology, Immunotherapy 73 (7), 133, 2024 | | 2024 |
| Prognostic stratification ability of the CPS+ EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy N Roussot, G Constantin, I Desmoulins, A Bergeron, L Arnould, F Beltjens, ... European Journal of Cancer 202, 114037, 2024 | | 2024 |
| 255P Prognostic stratification capacity of the CPS+ EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy N Roussot, G Constantin, I Desmoulins, C Kaderbhai, A Hennequin, ... Annals of Oncology 34, S285, 2023 | | 2023 |
| Phase II of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal … JD Fumet, A Bertaut, N Roussot, H Bellio, L Bengrine-Lefevre, J Vincent, ... Journal of Clinical Oncology 41 (16_suppl), e15563-e15563, 2023 | | 2023 |
Cédric RébéResearcher, centre GF Leclerc, France在 cgfl.fr 的电子邮件经过验证
Cédric RébéResearcher, centre GF Leclerc, France在 cgfl.fr 的电子邮件经过验证